Abstract
Graft failure is a life-threatening complication of allogeneic stem cell transplantation (SCT). We assessed the feasibility of performing a second SCT after such failure when fludarabine and antithymocyte globulin (ATG) are used for non-myeloablative conditioning and tacrolimus for graft-versus-host disease (GVHD) prophylaxis. Nine patients with SCTs for various hematologic malignancies were enrolled, eight with primary and one with secondary graft failure. The median time between the first and second SCT was 53 days. Eight patients had the same donor for their second SCT, and one had a cord blood transplant. Three patients were not evaluable because of early death; the other six had evidence of donor cell engraftment. Six of the nine patients developed acute grade II–IV GVHD, the main cause of death. Overall, we found that fludarabine and ATG conditioning before a second SCT allows engraftment of donor hematopoiesis. Future studies should include more intense GVHD prophylaxis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.
Donohue J, Homge M, Kernan NA . Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood 1993; 82: 1023–1029.
Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322: 485–494.
Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.
Storb R, Prentice RL, Thomas ED . Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977; 296: 61–66.
Wolff SN . Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29: 545–552.
Nemunaitis J, Singer JW, Buckner CD, Durnam D, Epstein C, Hill R et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–253.
Weisdorf DJ, Verfaillie CM, Davies SM, Filipovich AH, Wagner Jr JE, Miller JS et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995; 85: 3452–3456.
Fouillard L, Deconinck E, Tiberghien P, Deschaseaux ML, Solary E, Mugneret F et al. Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 943–946.
Remberger M, Ringden O, Ljungman P, Hagglund H, Winiarski J, Lonnqvist B et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 22: 73–78.
Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–459.
Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.
Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.
Chung IJ, Lee JJ, Park MR, Kook H, Cho SH, Hwang TJ et al. Allogeneic peripheral blood stem cell rescue of late graft failure after bone marrow transplantation in patients with aplastic anemia. J Korean Med Sci 2002; 17: 468–474.
Thomas E, Storb R, Clift RA, Johnson FL, Neiman PE, Lerner KG et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843.
Grandage VL, Cornish JM, Pamphilon DH, Potter MN, Steward CG, Oakhill A et al. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated bone marrow transplantation. Bone Marrow Transplant 1998; 21: 687–690.
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000; 111: 292–302.
Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G et al. Second HLA-identical sibling transplants for leukemic recurrence. Bone Marrow Transplant 1992; 80: 33–39.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jabbour, E., Rondon, G., Anderlini, P. et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40, 431–435 (2007). https://doi.org/10.1038/sj.bmt.1705760
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705760
Keywords
This article is cited by
-
Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review
Bone Marrow Transplantation (2022)
-
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen
International Journal of Hematology (2019)
-
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies
Journal of Cancer Research and Clinical Oncology (2017)
-
Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients
Bone Marrow Transplantation (2015)
-
Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation
Journal of Cancer Research and Clinical Oncology (2015)